A carregar...

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cephalalgia
Main Authors: Navratilova, Edita, Behravesh, Sasan, Oyarzo, Janice, Dodick, David W, Banerjee, Pradeep, Porreca, Frank
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412872/
https://ncbi.nlm.nih.gov/pubmed/32615788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420938652
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!